SCHEMBL436174

SCHEMBL436174

O=C(COc1ccc(CBr)cc1)c1ccccc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.60
RAB9A P51151 3/20 0.60
NPC1 O15118 2/20 0.60
SMN1; SMN2 Q16637 2/20 0.60
LMNA P02545 2/20 0.60
L3MBTL1 Q9Y468 2/20 0.60
MAPK1 P28482 1/20 0.60
CASP3 P42574 1/20 0.60
SENP7 Q9BQF6 1/20 0.60
SENP6 Q9GZR1 1/20 0.60
KMT2A Q03164 3/20 0.59
CES2 O00748 1/20 0.56
CES1 P23141 1/20 0.56
MEN1 O00255 2/20 0.55
PPARG P37231 1/20 0.54
KDM4E B2RXH2 1/20 0.49
ALDH1A1 P00352 1/20 0.49
GAA P10253 1/20 0.49
HTT P42858 1/20 0.49
PTPN1 P18031 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9786970 0.88 MAPT (0.74) MAPTRAB9ANPC1SMN1; SMN2LMNA
SCHEMBL9647757 0.85 MAPT (0.59) MAPTRAB9ANPC1SMN1; SMN2LMNA
SCHEMBL9651018 0.85 MAPT (0.59) MAPTRAB9ANPC1SMN1; SMN2LMNA
SCHEMBL433645 0.85 MAPT (0.62) MAPTRAB9ANPC1SMN1; SMN2LMNA
SCHEMBL9787068 0.85 LMNA (0.80) MAPTRAB9ANPC1SMN1; SMN2LMNA
SCHEMBL1068092 0.84 MAPT (0.69) MAPTRAB9ANPC1SMN1; SMN2LMNA
SCHEMBL28959509 0.83 NPC1 (0.60) MAPTRAB9ANPC1SMN1; SMN2LMNA
SCHEMBL2794292 0.83 MAPT (0.64) MAPTRAB9ANPC1SMN1; SMN2LMNA
Hydrochloric Acid SCHEMBL8136104 0.82 MAPT (0.67) MAPTRAB9ANPC1SMN1; SMN2LMNA
Methane SCHEMBL28765047 0.82 MAPT (0.67) MAPTRAB9ANPC1SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2595952-B1 AGONISTS OF GPR40 CONNEXIOS LIFE SCIENCES PVT LTD (IN) 2020-11-18 EP disclosed
EP-2595952-B1 AGONISTS OF GPR40 CONNEXIOS LIFE SCIENCES PVT LTD (IN) 2020-11-18 EP disclosed
US-9278915-B2 Agonists of GPR40 CONNEXIOS LIFE SCIENCES PVT LTD (IN) 2016-03-08 US disclosed
US-9278915-B2 Agonists of GPR40 CONNEXIOS LIFE SCIENCES PVT LTD (IN) 2016-03-08 US disclosed
US-9278915-B2 Agonists of GPR40 CONNEXIOS LIFE SCIENCES PVT LTD (IN) 2016-03-08 US disclosed
US-20130237571-A1 AGONISTS OF GPR40 Conexios Life Sciences PVT. LTD. (IN) 2013-09-12 US disclosed
US-20130237571-A1 AGONISTS OF GPR40 Conexios Life Sciences PVT. LTD. (IN) 2013-09-12 US disclosed
US-20130237571-A1 AGONISTS OF GPR40 Conexios Life Sciences PVT. LTD. (IN) 2013-09-12 US disclosed
EP-2595952-A1 AGONISTS OF GPR40 Connexios Life Sciences Pvt. Ltd. (IN) 2013-05-29 EP disclosed
WO-2012011125-A1 AGONISTS OF GPR40 CONNEXIOS LIFE SCIENCES PVT. LTD. (IN) 2012-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130237571-A1 AGONISTS OF GPR40 GPR65, GPR55, GPR68 MAPT 2792/4885RAB9A 2043/4885NPC1 513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.